Dashboard
Manage Tickers

ATAIATAI Life Sciences N.V.

Nasdaq atai.life


$ 1.23 $ 0.05 (4.2 %)    

Monday, 09-Sep-2024 15:59:41 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 455.25 $ 5.77 (1.29 %)
DIA $ 409.08 $ 4.58 (1.13 %)
SPY $ 546.60 $ 6.05 (1.12 %)
TLT $ 99.96 $ 0.43 (0.43 %)
GLD $ 231.58 $ 0.97 (0.42 %)
$ 1.24
$ 1.23
$ 1.22 x 1,717
$ 1.23 x 800
$ 1.22 - $ 1.28
$ 1.03 - $ 2.85
621,387
na
208.07M
$ 1.45
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-13-2024 06-30-2024 10-Q
2 05-15-2024 03-31-2024 10-Q
3 03-28-2024 12-31-2023 10-K
4 11-14-2023 09-30-2023 10-Q
5 08-10-2023 06-30-2023 10-Q
6 05-11-2023 03-31-2023 10-Q
7 03-24-2023 12-31-2022 10-K
8 11-10-2022 09-30-2022 10-Q
9 08-15-2022 06-30-2022 10-Q
10 05-16-2022 03-31-2022 10-Q
11 03-30-2022 12-31-2021 10-K
12 11-15-2021 09-30-2021 10-Q
13 08-16-2021 06-30-2021 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

psychedelic-drugs-market-set-to-grow-by-137b-by-2028-driven-by-mental-health-disorders-and-ai-integration
Psychedelic Drugs Market Set To Grow By $1...
09/05/2024 16:53:46

The global psychedelic drugs market is projected to grow by USD 1.37 billion by 2028, driven by mental health needs and AI adva...

hc-wainwright--co-reiterates-buy-on-atai-life-sciences-maintains-15-price-target
HC Wainwright & Co. Reiterates Buy on ATAI...
08/30/2024 16:01:53

HC Wainwright & Co. analyst Patrick Trucchio reiterates ATAI Life Sciences (NASDAQ:ATAI) with a Buy and maintains $15 pr...

atais-dmt-depression-drug-shows-promise-prepares-for-phase-ii-trial-and-future-collaboration-with-pharma-giant
Atai's DMT Depression Drug Shows Promise, ...
08/14/2024 18:34:49

Atai Life Sciences reports positive early data for its DMT-based depression treatment, VLS-01, and plans a Phase II trial targe...

atai-life-sciences-expects-cash-marketable-securities-and-committed-term-loan-funding-to-fund-operations-into-2026
atai Life Sciences Expects Cash, Marketabl...
08/13/2024 11:31:01

atai-life-sciences-q2-eps-036-down-from-021-last-year-license-revenue-273k-up-from-172k-prior-year
atai Life Sciences Q2 EPS $(0.36), Down Fr...
08/13/2024 11:30:28

hc-wainwright--co-reiterates-buy-on-atai-life-sciences-maintains-15-price-target
HC Wainwright & Co. Reiterates Buy on ATAI...
07/31/2024 12:29:39

HC Wainwright & Co. analyst Patrick Trucchio reiterates ATAI Life Sciences (NASDAQ:ATAI) with a Buy and maintains $15 pr...

cantor-fitzgerald-reiterates-overweight-on-atai-life-sciences
Cantor Fitzgerald Reiterates Overweight on...
06/21/2024 16:26:10

Cantor Fitzgerald analyst Charles Duncan reiterates ATAI Life Sciences (NASDAQ:ATAI) with a Overweight.

atai-life-sciences-announced-an-update-on-beckley-psytechs-phase-12a-trial-of-ele-101-for-major-depressive-disorder-with-initial-results-from-phase-1-and-the-dosing-of-the-first-patients-in-the-phase-2a-part-of-the-study
Atai Life Sciences Announced An Update On ...
06/20/2024 11:05:54

ELE-101 is a patent-protected, synthetic formulation of psilocin, designed to offer the therapeutic benefits of psilocybin in...

psychedelic-stocks-trip-up-after-fda-advisors-reject-mdma-for-ptsd-treatment
Psychedelic Stocks Trip Up After FDA Advis...
06/05/2024 19:26:42

FDA panel rejects MDMA therapy for PTSD, citing lack of evidence for benefits outweighing risks. Psychedelic stocks take a hit,...

whats-going-on-with-mindmed-and-psychedelic-stocks
What's Going On With MindMed And Psychedel...
06/05/2024 14:58:55

Mind Medicine (MindMed) shares are trading lower Wednesday after a Food and Drug Administration (FDA) panel rejected the approv...

hc-wainwright--co-reiterates-buy-on-atai-life-sciences-maintains-15-price-target
HC Wainwright & Co. Reiterates Buy on ATAI...
05/17/2024 17:16:08

HC Wainwright & Co. analyst Patrick Trucchio reiterates ATAI Life Sciences (NASDAQ:ATAI) with a Buy and maintains $15 pr...

atai-life-sciences-q1-eps-017-beats-018-estimate-cash-1887m
ATAI Life Sciences Q1 EPS $(0.17) Beats $(...
05/15/2024 11:57:21

ATAI Life Sciences (NASDAQ:ATAI) reported quarterly losses of $(0.17) per share which beat the analyst consensus estimate of $(...

pot-company-gets-license-to-open-psilocybin-service-center-the-sacred-mushroom-in-oregon
Pot Company Gets License To Open Psilocybi...
05/09/2024 13:29:42

atai-life-sciences-disclosed-dosing-of-first-patient-in-part-2-of-beckley-psytechs-phase-2a-study-exploring-bpl-003-adjunctive-to-ssris-in-patients-with-treatment-resistant-depression
Atai Life Sciences Disclosed Dosing Of Fir...
04/24/2024 11:08:03

psyched-dea-revisits-ban-on-two-psychedelics-farewell-russell-newcombe-podcast-episode-on-kanna--more
Psyched: DEA Revisits Ban On Two Psychedel...
04/17/2024 12:42:33

atai-life-sciences-announces-the-publication-of-beckley-psytechs-phase-1-study-of-bpl-003-in-the-journal-of-psychopharmacology
ATAI Life Sciences Announces the Publicati...
04/17/2024 11:03:16

atai Life Sciences (NASDAQ:ATAI) ("atai" or "Company"), a clinical-stage biopharmaceutical company aiming to tr...

cantor-fitzgerald-reiterates-overweight-on-atai-life-sciences
Cantor Fitzgerald Reiterates Overweight on...
04/04/2024 13:54:39

Cantor Fitzgerald analyst Charles Duncan reiterates ATAI Life Sciences (NASDAQ:ATAI) with a Overweight.

why-ulta-beauty-shares-are-trading-lower-by-around-14-here-are-other-stocks-moving-in-wednesdays-mid-day-session
Why Ulta Beauty Shares Are Trading Lower B...
04/03/2024 17:56:10

Shares of Ulta Beauty, Inc. (NASDAQ: ULTA) fell sharply during Wednesday’s session amid the company's presentation at the ...

signet-jewelers-dave--busters-entertainment-blue-owl-capital-and-other-big-stocks-moving-higher-on-wednesday
Signet Jewelers, Dave & Buster's Entertain...
04/03/2024 14:31:14

U.S. stocks were higher, with the Dow Jones gaining over 50 points on Wednesday.

maxim-group-upgrades-atai-life-sciences-to-buy-announces-6-price-target
Maxim Group Upgrades ATAI Life Sciences to...
04/03/2024 14:02:10

Maxim Group analyst Jason McCarthy upgrades ATAI Life Sciences (NASDAQ:ATAI) from Hold to Buy and announces $6 price target.

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION